During the past decade, Translational Genomics Research Institute (TGen) conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Translational Genomics Research Institute (TGen)" #1 sponsor was "ACADIA Pharmaceuticals Inc." with 2 trials, followed by "AVEO Pharmaceuticals, Inc." with 1 trials sponsored, "Celgene" with 1 trials sponsored, "Florida Institute for Human and Machine Cognition" with 1 trials sponsored and "National Human Genome Research Institute (NHGRI)" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Translational Genomics Research Institute (TGen)" #1 collaborator was "Translational Genomics Research Institute" with 2 trials as a collaborator, "Celgene Corporation" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Office of Naval Research (ONR)" with 1 trials as a collaborator and "SideOut Foundation" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Translational Genomics Research Institute (TGen)" are "Rett Syndrome" (2 trials), "Inflammation" (1 trials), "Metastatic Breast Cancer" (1 trials), "Metastatic Pancreatic Cancer" (1 trials) and "Oxidative Stress" (1 trials). Many other conditions were trialed in "Translational Genomics Research Institute (TGen)" in a lesser frequency.

Most popular intervention types in "Translational Genomics Research Institute (TGen)" are "Drug" (7 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "(will be assigned based on molecular profile and RPMA)" (1 trials), "ABI-007" (1 trials), "Gemcitabine, nab-Paclitaxel, GDC-0449" (1 trials), "Oxytocin nasal spray" (1 trials) and "Placebo nasal spray" (1 trials). Other intervention names were less common.

The vast majority of trials in "Translational Genomics Research Institute (TGen)" are 7 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Translational Genomics Research Institute (TGen)". 1 are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Translational Genomics Research Institute (TGen), undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Translational Genomics Research Institute (TGen), 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".